Ultragenyx Pharmaceutical (RARE) Form 3 Ultragenyx Pharmaceutical / Erik Harris ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Harris Erik

(Last) (First) (Middle)

60 LEVERONI COURT

(Street)

NOVATO CA 94949

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
06/11/2019

3. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
EVP & Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	9,861(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	07/06/2027	Common Stock	30,000	63.28	D
Stock Option (Right to Buy)	(3)	03/01/2028	Common Stock	3,900	48.43	D
Stock Option (Right to Buy)	(4)	03/01/2029	Common Stock	13,000	67.55	D

Explanation of Responses:

1. Includes 8,552 Restricted Stock Units ("RSUs") awarded under the Company's 2014 Incentive Plan. 6,737 of the RSUs vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Of the 6,737 RSUs, 2,250 were granted on July 6, 2017, 487 were granted on March 1, 2018, and 4,000 were granted on March 1, 2019. The remaining 1,815 RSUs vest with respect to 1/3rd of the underlying shares on each of April 19, 2020, May 6, 2020, and May 6, 2021.

2. 1/4th of the shares initially subject to the option vested on July 6, 2018; thereafter, 1/48th of the shares initially subject to the option shall vest monthly.

3. 1/4th of the shares initially subject to the option vested on March 1, 2019; thereafter, 1/48th of the shares initially subject to the option shall vest monthly.

4. 1/4th of the shares initially subject to the option shall vest on March 1, 2020; thereafter, 1/48th of the shares initially subject to the option shall vest monthly.

Remarks:

Ex. 24 - Power of Attorney

	/s/ Karah Parschauer, attorney-in-fact	06/21/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.